Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Pharmacology, Biochemistry, and Behavior|March 1, 1996
Central nervous system characterization of the new cholecystokininB antagonist LY288513D R Helton, J E Berger, J F Czachura, et al.
Neuropharmacology|March 28, 1998
LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in ratsD R Helton, J P Tizzano, J A Monn, et al.
Research Communications in Chemical Pathology and Pharmacology|April 1, 1979
Morphine-induced behavioral disruption in rats chronically depleted of brain dopamineM J Kallman, R M Spencer, A T White, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 7, 1998
Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptorsD R Helton, J P Tizzano, J A Monn, et al.
Arzneimittel-Forschung|January 1, 1996
General pharmacology of insulin lispro in animalsD R Helton, J L Zimmermann, A Heim, et al.
Pharmacology, Biochemistry, and Behavior|July 1, 1984
Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activityB R Martin, M J Kallman, G F Kaempf, et al.
Pharmacology, Biochemistry, and Behavior|November 1, 1982
Effects of nicotine on the visual evoked responseP P Woodson, K Baettig, M W Etkin, et al.
Regulatory Toxicology and Pharmacology : RTP|August 1, 2017
Considerations on nonclinical approaches to modeling risk factors of suicidal ideation and behaviorS M G Goody, K E Cannon, M Liu, et al.
Pageof 4